Newsletters

Q1 2023 Excelsior Newsletter

Drug Trends to Watch, Actions to Consider by Robert Kordella, RPh, MBASenior Vice President and Chief Clinical Officer DIABETES Rising prescription costs related to the

Read More »

Q3 2022 Excelsior Newsletter

Excelsior’s Opinion on So-Called “Vision Enhancement Products” by Robert Kordella, RPh, MBA, Chief Clinical Officer Three products have come to market recently that are being

Read More »

Q2 2022 Excelsior Newsletter

Humira Savings on the Horizon? by Robert Kordella, RPh, MBA, Chief Clinical Officer In 2021, Humira (adalimumab) amassed $21 billion in sales in the U.S.

Read More »

Q3 2021 Excelsior Newsletter

Diabetes: What’s driving non-specialty trend? by Matt Jarvis, PharmD, Vice President, Pharmacy Practice Leader As specialty pharmacy continues to outpace other healthcare benefits spend, the

Read More »

Q2 2021 Excelsior Newsletter

Dispense As Written Prescription Instructions and Their Impact on Plan Sponsors and Participants by Joe Schmidt, MBA, Vice President | Team Lead   Before the

Read More »

Q1 2021 Excelsior Newsletter

Common Sense Management of Narcolepsy and Cataplexy by Bob Kordella, R.Ph., MBA, Chief Clinical Officer  The Mayo Clinic provides a simple definition of narcolepsy and

Read More »

Q4 2020 Excelsior Newsletter

November 30, 2020:Where We Are Today And When Will New Vaccines Be Approved? by Bob Kordella, R.Ph., MBA, Chief Clinical Officer Worldwide there were 48

Read More »

Q3 2020 Excelsior Newsletter

COVID-19 Vaccine Update by Bob Kordella, R.Ph., MBA, Chief Clinical Officer As several COVID-19 vaccine candidates work their way through the clinical trials process, many

Read More »